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1. Introduction 
Two new vitamin D3 metabolites bearing a lactone 
moiety in the side chain have been isolated: 25OH- 
D,26,23-lactone [l]; and 1~,25-(OH)~D~-26,23- 
lactone [2,3]. The stereochemistry of both metabolites 
is still unknown. Although 4 possible diastereoiso- 
mers of 25-OH-D3-26,23-lactone have been synthe- 
sized [4-81, they have not been directly compared to 
the natural metabolite. We have reported the isolation 
of a new metabolite, DA and proposed that its 
structure was tentatively determined to be la,25 
(OH)zD3-26,23-lactone without measurement of IR 
spectrum [3]. 
23@)25(S)-25-OH-D3-26,23-la&one, 23@)25(R)- 
25-OH-Da-26,23-lactone and 23@)25(R)-25-OH- 
D,26,23-lactone were chemically synthesized as 
in [7,8]. 
2.2. Preparation and purification of 25-OH-D3- 
26,234actone in rat serum 
We now report the definite determination of 
stereochemical configuration of 25-OH-D,-26,23- 
lactone and the structural determination including 
stereochemistry of the metabolite Dxl, la,25- 
(OH)zDs-26,23-lactone. 
2. Materials and methods 
2.1. Compounds 
We synthesized 25-OH-D3, 24,25-(OH)2D3, 







vitamin D,-26,23-lactone; 23(R)25(S)-lo1,25-(OH),D,- 
26,23-la&one, 23(R)25(S)-la,25dihydroxyvitamin D,- 
26,23-lactone; 23(S)25-(OH),D,, 23(S)25dihydroxyvitamin 
D,; 25(X)26-(OH),D,, 25(S)26dihydroxyvitamin D,; HPLC, 
high-pressure liquid chromatography 
Male weanling rats of the Wistar strain were fed a 
normal vitamin D3-containing diet (Nippon Clea 
Corp. CE-2: Ca, 1 .O%; P, 1 .O%; D3, 2000 IU/kg) for 
8 weeks ad libitum. The 150 rats were then dosed 
2 times intramuscularly with 4 X 1 OS IU vitamin D3 
in 100 ~1 ethanol at 3 day intervals. Three days after 
the second dose, the rats were anesthetized with ether 
and their blood was withdrawn from the abdominal 
aorta. The serum (600 ml) was diluted with the same 
volume of water and then extracted with 2 vol. chlo- 
(1: 1). The chloroform extracts of 
serum was chromatographed on a 1.5 X 25 cm 
Sephadex LH-20 column eluted with chloroform: 
n-hexane (65:35). The 24,25-(OH)*D3 fraction from 
the Sephadex LH-20 column was then subjected to 
HPLC on a Hitachi Model 635 equipped with a 
4.6 X 250 mm Zorbax Sil column eluted with 9% iso- 
propanol in n-hexane at a flow rate of 1 ml/min. 
25-OH-D3-26,23-la&one fraction was rechromato- 
graphed by using the same solvent. 25-OH-D,26,23- 
lactone was further purified by HPLC using a Zorbax 
Sil column eluted with 1.5% methanol in dichloro- 
methane at a flow rate of 1 ml/min. 
2.3. Preparation and purification of 1(~,25-(OH)~D3- 
26,234actone in rat serum 
Male weanling Wistar rats were maintained as 
above. The 150 rats were each given orally by stem- 
ach tubes 100 pg la,25-(OH)2D3 in 1 ml 5% ethanol 
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in 0.2% Triton X-l 00 solution. At 7-8 h after dosing, 
the rats were anesthetized with ether and their blood 
was withdrawn from the abdominal aorta. The 
extraction and purification of 1q25-(OH)2Ds-26,23- 
lactone was done as in [2,3]. 
2.4.1 a-Hydroxylation of 23(R)2S(S)-25-OH-D3- 
26,23-lactone and 23(S)25(R)-25-OH-D,26,23- 
lactone by chick kidney homogenate 
Four-week-old White Leghorn cockerels were 
raised on a vitamin D-deficient diet [ 111. The chicks 
were sacrificed, their kidneys were taken and 10% tis- 
sue homogenate in 0.25 M sucrose was prepared with 
the aid of a Potter-Elvehjem homogenizer fitted with 
a Teflon pestle. To 24 ml homogenate (13 mg pro- 
tein/ml) in a 300 ml flask, 56 ml reaction mixture 
containing 30 mM Tris-HCl (pH 7.4), 3.6 mM MgC12. 
50 mM sucrose and 20 mM sodium succinate was 
added as in [lo]. The incubation was initiated by 
addition of 25 nmol 23@)25(S)-25OH-Ds-26,23- 
lactone or 23(S)25@)-25-OH-Da-26,23-lactone in 
0.5 ml ethanol. The incubations were carried out at 
37°C for 60 min with shaking; 160 ml chloroform: 
methanol (1: 1) was added to each flask to terminate 
the reaction. The metabolites of 25-OH-Ds-26,23- 
lactone were separated and purified by Sephadex 
LH-20 column chromatography and HPLC using a 
Zorbax Sil column as described above. 
2.5. Spectroscopy 
Mass spectra were determined with a Simadzu- 
LKB mass spectrometer Model 9000 in the direct 
probe inlet mode. The Fourier transform infrared 
(FT-IR) spectra were obtained by using a JEOL 
Model JIR40X (Japan Electric Optical Lab. Ltd.). 
3. Results and discussion 
We obtained the highly purified 25OH-Ds-26,23- 
lactone from rat serum as in [9] with slight modifica- 
tions. The natural metabolite was directly compared 
to 2 diastereoisomers, 23(S)25@)-25-OH-Da-26,23- 
lactone and 23@)25(S)-25-OH-Ds-26,23-lactone 
stereospecifically synthesized by [7,8]. Both com- 
pounds were chosen for comparison because of higher 
similarity of NMR spectrum of either compound to 
that of natural metabolite than the other 2 diastereo- 
isomers [ 1,4,6]. The 2 synthetic diastereoisomers, 
23(S)25@)-25-OH-Ds-26,23-lactone and 23@)25(S)- 
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25OH-Ds-26,23-lactone, could be separated into 
each peak by HPLC (fig.1 A). The former isomer 
comigrated with the natural metabolite (fig.1 B). The 
IR spectra and mass spectra of the natural metabolite 
and those of 23@)25(R)-25-OH-Da-26,23-lactone 
were completely superimposable (fig.2,3). Thus, the 
stereochemistry of the natural metabolite was defi- 
nitely determined to be 23@)25(R)-25-OH-Da- 
26,23-lactone. 
The other metabolite, Dxl was obtained from 
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Fig.1. High-pressure liquid chromatographic profiles of dia- 
stereoisomers of synthetic 25-01-i-D,P26,23-lactone and nat- 
ural 25-OH-D,-26,23-lactone: (A) synthetic 25-OHD- 
26,23-lactones; (B) natural 25-OH-D,-26,23-lactone from rat 
serum. 25-OH-D,-26,23-Lactones were subjected to high 
pressure liquid chromatography on a 4.6 X 250 mm Zorbax 
Sil column eluted with 9% isopropanol in n-hexane at a flow 
rate of 1 ml/min. 
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Fig.2. Fourier transform infrared spectrum of natural 25-OH-D,-26,23-lactone from rat serum. 
rat serum by the HPLC method in [2,3]. The struc- 
tural elucidation of Dxl was made by spectroscopic 
data (IR and mass) and by direct comparison with 
23(S)25(R)-1q25-(0H)2D,26,23-lactone and 
23@)25($)-1(~,25-(OH)~D,-26,23-lactone, which 
were bioconverted from the synthetic diastereoiso- 
mers of 25-OH-Da-26,23-lactone. The IR spectrum 
of the natural metabolite, Dxl, is shown in fig.4. It 
indicates the presence of an absorption at 1776 cm-’ 
due to y-la&one moiety. So, the metabolite, Dxl, was 
confirmed to have y-la&one in the side chain. The 
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Fig.3. Mass spectrum of natural 25XIH-D,-26,23-lactone from rat serum. 
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Fig.4. Fourier transform infrared spectrum of natural lor,25-(OH),D,-26,23-lactone from rat serum. 
269,25 1, 152 and 134 as in [3]. It shows the very 
similar fragmentation pattern to that of the natural 
25OH-Da-26,23-lactone. 
Each diastereoisomer, 23(@25(ZZ)-la,25(OH),Da- 
26,23-lactone and 23@)25(S)-la,25(OH)2Da-26,23- 
lactone, prepared from the corresponding synthetic 
isomers by 1 cw-hydroxylation with kidney homoge- 
nate, could be separable into peaks by HF’LC (fig.5). 
The former isomer comigrated together with the nat- 
ural metabolite Dxl. Thus, the structure of Dxl was 
identified unequivocally to be 23@)25(R)-la,25- 
(OH)2Da-26,23-lactone. 
These results demonstrate that 2 lactonic vitamin 
Da metabolites have the same stereochemical configu- 
ration 23(S)25(R) at C-23 and C-25 positions. It can 
be considered that a particular enzymatic system may 
be involved in the biotransformation from 25-OH-D3 
or lc~,25-(OH)~D~ to be corresponding lactonic metab- 
olites. 
Fig.5, High-pressure liquid chromatographic profiles of dia- 
stereoisomers of bioconverted 1~~,25-(OH),D,P26,23-lactone 
and natural la,25-(OH),D,-26,23-lactone: (A) bioconverted 
23(S)25(R)- and 23(R)25(S)-lor,25-(0H),D,-26,23-lactone 
by chick kidney homogenate; (B) natural lor,25-(OH),D,- 
26,23-lactone from rat serum. 1~~,25-(OH),D,~26,23-Lac- 
tones were subjected to high-pressure liquid chromatography 
on a 4.6 X 250 mm Zorbax Sil column eluted with 20% iso- 
propanol in n-hexane at a flow rate of 1 ml/min. 
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This enzymatic system may be activated when the 
levels of some vitamin D3 metabolites in plasma or 
the tissues reach far higher than normal physiological 
levels. The biotransformation pathways of lactonic 
metabolites are also very interesting. 
It can be assumed that metabolites such as 23(S)25- 
(OH)2D3 [ 121 or 25(S)26-(OH)zD, [ 131 may be 
involved as one of the precursors of 23(5)25(R)-25 
OH-Da-26,234actone. With 25(S)26-(OH),D3 as a 
precursor, the stereochemical inversion of hydroxy 
group at C-25 position should occur during the course 
of lactone formation. Thus, it might be reasonable to 
consider that oxidation reactions such as as hydrox- 
ylation take place initially on the C-23 methylene 
group, followed by oxidation of the C-26 methyl 
group. 
The biological and physiological functions of the 
lactonic metabolites have been investigated, but they 
remain still undefined. Further investigations on these 
problems are now in progress. 
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